Exome analysis identifies brody myopathy in a family diagnosed with malignant hyperthermia susceptibility

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 6, 2014, Pages 472-483

  Sambuughin, Nyamkhishig ^a,b   Zvaritch, Elena ^c   Kraeva, Natasha ^d   Sizova, Olga ^c   Sivak, Erica ^e   Dickson, Kelley ^b   Weglinski, Margaret ^f   Capacchione, John ^b   Muldoon, Sheila ^b   Riazi, Sheila ^d   Hamilton, Susan ^g   Brandom, Barbara ^e   Maclennan, David H ^c  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f MAYO CLINIC   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Brody myopathy; Malignant hyperthermia; RYR1; SERCA1

Indexed keywords

EID: 84938740273     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.91     Document Type: Article

References (43)

1. Ahn, W., M. G. Lee, K. H. Kim, and S. Muallem. 2003. Multiple effects of SERCA2b mutations associated with Darier’s disease. J. Biol. Chem. 278:20795–20801.
2. Allen, G. C., M. G. Larach, and A. R. Kunselman. 1998. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 88:579–588.
3. Brandom, B. W., S. Bina, C. A. Wong, T. Wallace, M. Visoiu, P. J. Isackson, et al. 2013. Ryanodine receptor type 1 variants in the malignant hyperthermia-susceptible population of the United States. Anesth. Analg. 116:1078–1086.
4. Brini, M., and E. Carafoli. 2009. Calcium pumps in health and disease. Physiol. Rev. 89:1341–1378.
5. Brody, I. A. 1969. Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor. N. Eng. J. Med. 281:187–192.
6. Broman, M., A. Gehrig, G. Islander, M. Bodelsson, E. Ranklev-Twetman, H. Ruffert, et al. 2009. Mutation screening for the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Br. J. Anaesth. 102:642–649.
7. Burkman, J. M., K. L. Posner, and K. B. Domino. 2007. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 106:901–906.
8. Dainese, M., M. Quarta, A. D. Lyfenko, C. Paolini, M. Canato, C. Reggiani, et al. 2009. Anesthetic-and heat-induced sudden death in calsequestrin-1-knockout mice. FASEB J. 23:1710–1720.
9. Dlamini, N., N. C. Voermans, S. Lillis, K. Stewart, E. J. Kamsteeg, G. Drost, et al. 2013. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul. Disord. 23:540–548.
10. Exome Variant Server. NHLBI exome sequencing project. Seattle, WA. Available at www.evs.gs.washington.edu/EVS/ (accessed 04 March 2014).
11. Gonsalves, S. G., D. Ng, J. J. Johnston, J. K. Teer, P. D. Stenson, D. N. Cooper, et al.; NISC Comparative Sequencing Program. 2013. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology 119:1043–1053.
12. Groom, L., S. M. Muldoon, Z. Z. Tang, B. W. Brandom, M. Bayarsaikhan, S. Bina, et al. 2011. Identical de novo mutation in the RYR1 gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 115:938–945.
13. Guglielmi, V., G. Vattemi, F. Gualandi, N. C. Voermans, M. Marini, C. Scotton, et al. 2013. SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers. Mol. Genet. Metab. 110:162–169.
14. Iles, D. E., F. Lehmann-Horn, S. W. Scherer, L. C. Tsui, D. Olde-Weghuis, R. F. Suijkerbuijk, et al. 1994. Localization of the gene encoding the alpha-2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum. Mol. Genet. 3:969–975.
15. 2+-adenosine triphosphatase in sarcoplasmic reticulum (Brody’s disease). Ann. Neurol. 20:38–49.
16. Kraeva, N., E. Zvaritch, W. Frodis, O. Sizova, A. Kraev, D. H. MacLennan, et al. 2013. CASQ1 gene is an unlikely candidate for malignant hyperthermia susceptibility in the North American population. Anesthesiology 118:344–349.
17. Larach, M. G. 1989. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth. Analg. 69:511–515.
18. Larach, M. G., B. W. Brandom, G. C. Allen, G. A. Gronert, and E. B. Lehman. 2008. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 108:603–611.
19. Løseth, S., N. C. Voermans, T. Torbergsen, S. Lillis, C. Jonsrud, S. Lindal, et al. 2013. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. J. Neurol. 260:1504–1510.
20. 2+ signaling and muscle disease. Eur. J. Biochem. 267:5291–5297.
21. Maclennan, D. H., and E. Zvaritch. 2011. Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum. Biochim. Biophys. Acta 1813: 948–964.
22. 2+-binding translocation domain of SERCA1: physiological correlates in Brody disease. Acta Physiol. Scand. Suppl. 643:55–67.
23. Meng, X., B. Xiao, S. Cai, X. Huang, F. Li, J. Bolstad, et al. 2007. Three-dimensional localization of serine 2808, a phosphorylation site in Cardiac Ryanodine Receptor. J. Biol. Chem. 282:25929–25939.
24. Monnier, N., I. Marty, J. Faure, C. Castiglioni, C. Desnuelle, S. Sacconi, et al. 2008. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum. Mutat. 29:670–678.
25. 2+ ATPase, are associated with Brody disease. Nat. Genet. 14:191–194.
26. Odermatt, A., P. E. Taschner, S. W. Scherer, B. Beatty, V. K. Khanna, D. R. Cornblath, et al. 1997. Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: absence of structural mutations in five patients with Brody disease. Genomics 45:541–553.
27. 2+ ATPase (SERCA1) and is associated with Brody disease. Hum. Genet. 106:482–491.
28. Ording, H., V. Brancadoro, S. Cozzolino, F. R. Ellis, V. Glauber, E. F. Gonano, et al. 1997. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand. 41:955–966.
29. Paul-Pletzer, K., T. Yamamoto, N. Ikemoto, L. S. Jimenez, H. Morimoto, P. G. Williams, et al. 2005. Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem. J. 387:905–909.
30. Robinson, R., P. Hopkins, A. Carsana, H. Gilly, J. Halsall, L. Heytens, et al. 2003. Several interacting genes influence the malignant hyperthermia phenotype. Hum. Genet. 112: 217–218.
31. Rosenberg, H., N. Sambuughin, and R. T. Dirksen. 1997–2012. Malignant hyperthermia susceptibility in GeneReviews at GeneTests: medical genetics information resource. University of Washington, Seattle, WA. Available at www.genetests.org.
32. 2 mutations in a family presented with fatal infantile hyperthermia. J. Hum. Genet. 58:226–228.
33. Tompa, P., P. Buzder-Lantos, A. Tantos, A. Farkas, A. Szilagyi, Z. Banoczi, et al. 2004. On the sequential determinants of calpain cleavage. J. Biol. Chem. 279:20775–20785.
34. Toro, M., M. Olive, M. C. Dalakas, K. Sivakumar, J. M. Bilbao, F. Tyndel, et al. 2013. Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure in families with diverse ethnic origins. BMC Neurol. 13:29.
35. Valdmanis, P. N., I. A. Meijer, A. Reynolds, A. Lei, P. MacLeod, D. Schlesinger, et al. 2007. Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia. Am. J. Hum. Genet. 80:152–161.
36. Vattemi, G., F. Gualandi, A. Oosterhof, M. Marini, P. Tonin, P. Rimessi, et al. 2010. Brody disease: insights into biochemical features of SERCA1 and identification of a novel mutation. J. Neuropathol. Exp. Neurol. 69:246–252.
37. Visoiu, M., M. C. Young, K. F. Wieland, and B. W. Brandom. 2014. Anesthetic drugs and onset of malignant hyperthermia. Anesth. Analg. 118:388–396.
38. Voermans, N. C., A. E. Laan, A. Oosterhof, T. H. van Kuppevelt, G. Drost, M. Lammens, et al. 2012. Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: a review of literature and a cross-sectional clinical study in 17 patients. Neuromuscul. Disord. 22:944–954.
39. Vukcevic, M., M. Broman, G. Islander, M. Bodelsson, E. Ranklev-Twetman, C. R. Müuller, et al. 2010. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease. Anesth. Analg. 111:185–190.
40. Wang, Y., A. T. Bruce, C. Tu, K. Ma, L. Zeng, P. Zeng, et al. 2011. Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes. J. Cell Sci. 124:3568–3580.
41. 2+ release channel. J. Biol. Chem. 272:25051–25061.
42. 2+-binding proteins. Prog. Clin. Biol. Res. 168:19–23.
43. 2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc. Natl. Acad. Sci. USA 106:21813– 21818.